Are you attending #ASTRO2021 this year? Meet with @Veracyte’s Elai Davicioni, PhD to talk about prostate cancer genomics!
Decipher by Veracyte
1,486 posts
Decipher by Veracyte
@Decipher_VCYT
Veracyte offers Decipher genomic tests for urologic cancers.
- Check out @UroToday's video featuring leading #ProstateCancer physicians discussing an analysis of the phase 3 RTOG 0126 study that validates the performance of @Veracyte's #Decipher Prostate Genomic Classifier as a biomarker for men w/ #intermediate-risk disease.
- Decipher Prostate Biopsy is the first genomic test to receive Medicare coverage for men diagnosed with favorable and unfavorable intermediate-risk prostate cancer! #Decipher #ProstateCancer #biomarkers #Medicare prn.to/33LSq0W
- Decipher predicts OS and is the 1st genomic classifier validated in a Phase III RCT in prostate cancer. Decipher identified high-risk men likely to benefit from the addition of hormones to SRT. @DrSpratticus gives his view on this important development.
- Not all newly-diagnosed, clinically high-risk #ProstateCancer patients are the same. Check out this paper that discusses the definition and validation of a "favorable" high-risk group.
- Hear from the experts! 📢 @UCSFUrology urologist @dr_coops, @JEFFUrology radiation oncologist @RobertDen6 and @miami_urology urologist @sanojpunnen discuss the increasing importance of biomarkers in determining treatment for prostate cancer patients.
- A new @urotoday video features @DrSpratticus and @ashleyrossmdphd discussing an independent systematic review of #Decipher in 42 studies w/ 30k+ patients that revealed the test to be independently prognostic for OS, metastasis, and other endpoints. Watch: bit.ly/2ZsT6Zn
00:00 - Great prospective study by @RobertDen6 and colleagues defining the clinical utility and benefit of #Decipher in men following prostatectomy further validating the previous PRO-IMPACT trial results
- A new study from @EurUrolOpen of post-biopsy prostate cancer patients showed tumor volume was not associated with aggressive tumor biology (Decipher score) in GG1 disease, suggesting that in these patients, tumor volume may not be informative for active surveillance decisions.
- As featured in the @urotoday commentary with @AndreaNecchi, #Decipher identifies #MIBC patients with a specific molecular subtype that are most likely to benefit from neoadjuvant immunotherapy with @Merck #KEYTRUDA prn.to/2zwA8am
- Listen to part 2 of @UroToday’s 3-part series! @DrSpratticus discusses RTOG 9601 & GETUG-AFU on the addition of hormone therapy to RT in post-RP patients with a rising PSA & how he utilizes the @Veracyte Decipher prostate test for treatment decisions bit.ly/3yeFOP5
- #Decipher analysis of the RCT SPARTAN, a trial of apalutamide in #prostatecancer (nmCRPC) patients, found that the Decipher test and #DecipherGRID basal-luminal subtypes may be biomarkers of response to apalutamide+ADT. jamanetwork.com/journals/jamao… @Veracyte @decipher_bio @felixfengmd
- Get a fresh perspective on genomics in the post-prostatectomy setting! Watch Part 1 of @UroToday’s 3-part series featuring Dr. Spratt, Dr. Ross, and Dr. Dal Pra discussing new data from SAKK 09/10 and RTOG 96-01, and the new #Decipher Prostate RP report! bit.ly/37UEoOP
